UNCY
|Unicycive Therapeutics Inc
NASDAQ
USD 0.75
-0.01|-1.92%
Current Price
USD 0.75
Change
USD -0.01 (-1.92%)
P/E Ratio
0
Dividend Yield
Market Cap
73.69M
Volume
2.22M
Open
USD 0.78
Previous Close
USD 0.77
52-Week High
USD 0.96
52-Week Low
USD 0.20
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, li...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Shalabh K. Gupta M.D., MPA
Employees:22
Headquarters:Los Altos, USA
Website:unicycive.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions